Early TAVR Superior for Asymptomatic Aortic Stenosis 02/05/26
Welcome to Cardiology Today – Recorded February 05, 2026. This episode summarizes 5 key cardiology studies on topics like risk prediction and heart failure. Key takeaway: Early TAVR Superior for Asymptomatic Aortic Stenosis.
Article Links:
Article 1: PREVENT Equations in Young Adults: Fairness, Calibration, and Performance Across Racial and Ethnic Groups. (Journal of the American College of Cardiology)
Article 2: 1-Year Outcomes of Novel Balloon-Expandable vs Contemporary Transcatheter Heart Valves in Severe Aortic Stenosis: The LANDMARK Trial. (Journal of the American College of Cardiology)
Article 3: Left Ventricular Health and TAVR Timing in Asymptomatic Severe Aortic Stenosis: Analysis From the EARLY TAVR Trial. (Journal of the American College of Cardiology)
Article 4: Heart failure in the Portuguese population aged ≥50 years: prevalence and phenotypes in the PORTHOS study. (European heart journal)
Article 5: Subvalvular aortic stenosis in adults: clinical course and long-term outcomes. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/early-tavr-superior-for-asymptomatic-aortic-stenosis-02-05-26/
📚 Featured Articles
Article 1: PREVENT Equations in Young Adults: Fairness, Calibration, and Performance Across Racial and Ethnic Groups.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41636665
Summary: Cardiovascular disease is increasing among young adults, highlighting a critical need for effective primary prevention strategies. The American Heart Association’s PREVENT (Predicting Risk of Cardiovascular Disease Events) equations estimate risk for cardiovascular disease, atherosclerotic cardiovascular disease, and heart failure. This analysis provided insights into the performance and algorithmic fairness of these base and Social Deprivation Index-augmented PREVENT equations across various racial and ethnic groups. The study emphasized the importance of equitable and accurately calibrated risk prediction tools for diverse young adult populations.
Article 2: 1-Year Outcomes of Novel Balloon-Expandable vs Contemporary Transcatheter Heart Valves in Severe Aortic Stenosis: The LANDMARK Trial.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41384893
Summary: The LANDMARK trial found that the Myval balloon-expandable Transcatheter Heart Valve (T. H. V.) series was noninferior to the most commonly used contemporary SAPIEN and Evolut Series T. H. V.s for the 30-day early safety endpoint. This finding was observed in participants with symptomatic severe native aortic stenosis. The study thereby established the initial safety profile of the novel Myval valve in comparison to established devices. Further evaluation of its one year clinical outcomes, hemodynamic performances, and quality of life is ongoing.
Article 3: Left Ventricular Health and TAVR Timing in Asymptomatic Severe Aortic Stenosis: Analysis From the EARLY TAVR Trial.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41128701
Summary: The EARLY TAVR trial definitively demonstrated that early Transcatheter Aortic Valve Replacement (TAVR) was superior to clinical surveillance for patients with asymptomatic severe aortic stenosis. This finding revealed a clear benefit of early intervention in improving patient outcomes. The subsequent analysis examined how baseline Left Ventricular (L. V.) health impacted this treatment effect and observed longitudinal L. V. health under different treatment strategies. These observations underscore the critical role of L. V. function in optimizing management decisions for asymptomatic severe aortic stenosis.
Article 4: Heart failure in the Portuguese population aged ≥50 years: prevalence and phenotypes in the PORTHOS study.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41641552
Summary: Heart failure constitutes a significant global health burden, with its true prevalence often uncertain due to heterogeneous study designs and evolving diagnostic criteria. The Portuguese Heart Failure Prevalence Observational Study (PORTHOS) investigated the prevalence and phenotypic distribution of heart failure in community-dwelling adults aged 50 years and older in mainland Portugal. This cross-sectional, population-based study provided a detailed epidemiological snapshot of heart failure within this specific European demographic. The findings from PORTHOS are essential for understanding regional disease burden and informing public health strategies.
Article 5: Subvalvular aortic stenosis in adults: clinical course and long-term outcomes.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41635281
Summary: This study delineated the clinical course and long-term outcomes for adults diagnosed with subvalvular aortic stenosis, utilizing prospectively registered data from the Dutch Congenital Cor Vitia registry. Researchers comprehensively assessed all-cause mortality, subvalvular aortic stenosis re-operation rates, and significant cardiovascular events, including arrhythmias and heart failure. The investigation also tracked longitudinal changes in echocardiographic peak velocity and interventricular septal thickness. Patients received an extensive follow-up period averaging 17.1 years, providing robust data on disease progression and long-term management challenges.
📝 Transcript
Today’s date is February 05, 2026. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. PREVENT Equations in Young Adults: Fairness, Calibration, and Performance Across Racial and Ethnic Groups. Cardiovascular disease is increasing among young adults, highlighting a critical need for effective primary prevention strategies. The American Heart Association’s PREVENT (Predicting Risk of Cardiovascular Disease Events) equations estimate risk for cardiovascular disease, atherosclerotic cardiovascular disease, and heart failure. This analysis provided insights into the performance and algorithmic fairness of these base and Social Deprivation Index-augmented PREVENT equations across various racial and ethnic groups. The study emphasized the importance of equitable and accurately calibrated risk prediction tools for diverse young adult populations.
Article number two. 1-Year Outcomes of Novel Balloon-Expandable vs Contemporary Transcatheter Heart Valves in Severe Aortic Stenosis: The LANDMARK Trial. The LANDMARK trial found that the Myval balloon-expandable Transcatheter Heart Valve (T. H. V.) series was noninferior to the most commonly used contemporary SAPIEN and Evolut Series T. H. V.s for the 30-day early safety endpoint. This finding was observed in participants with symptomatic severe native aortic stenosis. The study thereby established the initial safety profile of the novel Myval valve in comparison to established devices. Further evaluation of its one year clinical outcomes, hemodynamic performances, and quality of life is ongoing.
Article number three. Left Ventricular Health and TAVR Timing in Asymptomatic Severe Aortic Stenosis: Analysis From the EARLY TAVR Trial. The EARLY TAVR trial definitively demonstrated that early Transcatheter Aortic Valve Replacement (TAVR) was superior to clinical surveillance for patients with asymptomatic severe aortic stenosis. This finding revealed a clear benefit of early intervention in improving patient outcomes. The subsequent analysis examined how baseline Left Ventricular (L. V.) health impacted this treatment effect and observed longitudinal L. V. health under different treatment strategies. These observations underscore the critical role of L. V. function in optimizing management decisions for asymptomatic severe aortic stenosis.
Article number four. Heart failure in the Portuguese population aged ≥50 years: prevalence and phenotypes in the PORTHOS study. Heart failure constitutes a significant global health burden, with its true prevalence often uncertain due to heterogeneous study designs and evolving diagnostic criteria. The Portuguese Heart Failure Prevalence Observational Study (PORTHOS) investigated the prevalence and phenotypic distribution of heart failure in community-dwelling adults aged 50 years and older in mainland Portugal. This cross-sectional, population-based study provided a detailed epidemiological snapshot of heart failure within this specific European demographic. The findings from PORTHOS are essential for understanding regional disease burden and informing public health strategies.
Article number five. Subvalvular aortic stenosis in adults: clinical course and long-term outcomes. This study delineated the clinical course and long-term outcomes for adults diagnosed with subvalvular aortic stenosis, utilizing prospectively registered data from the Dutch Congenital Cor Vitia registry. Researchers comprehensively assessed all-cause mortality, subvalvular aortic stenosis re-operation rates, and significant cardiovascular events, including arrhythmias and heart failure. The investigation also tracked longitudinal changes in echocardiographic peak velocity and interventricular septal thickness. Patients received an extensive follow-up period averaging 17.1 years, providing robust data on disease progression and long-term management challenges.
Thank you for listening. Don’t forget to subscribe.
🔍 Keywords
risk prediction, heart failure, health equity, EARLY TAVR trial, aortic regurgitation, left ventricular health, echocardiography, aortic stenosis, PORTHOS study, young adults, prevalence, cardiovascular disease, congenital heart disease, noninferiority, epidemiology, Myval, TAVR, long-term outcomes, phenotypes, PREVENT equations, clinical surveillance, subvalvular aortic stenosis, transcatheter heart valve, asymptomatic aortic stenosis.
ℹ️ About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • Follow